

The Beau Biden Cancer Moonshot and the NCI Blue Ribbon Panel Recommendations


NAACCR Registry of the Future Presentation

June 19, 2017

The Beau Biden Cancer Moonshot

- Accelerate progress in cancer, including prevention & screening
 - From cutting edge basic research to wider uptake of standard of care
- Encourage greater cooperation and collaboration
 - Within and between academia, government, and private sector
- Enhance data sharing

The Cancer Moonshot aims to accelerate progress and do in 5 years what would have taken 10 years.



Blue Ribbon Panel recommendations (Oct); Implementation Working Groups established (Jan)
cancer.gov/brp

- *The 21st Century Cures Act, passed by Congress in December 2016, authorizes \$1.8 billion in funding for the Beau Biden Cancer MoonshotSM over seven years, starting with \$300 million for FY 2017.*
- *NCI has established implementation teams to identify how to deploy those funds to accelerate cancer research under 10 topics areas recommended by the Blue Ribbon Panel.*
- *Funding opportunities currently open for applications are posted on Cancer.gov. Researchers with an interest in these areas are encouraged to apply.*

CANCER MOONSHOT

[Task Force](#)

Blue Ribbon Panel Report

[Supporting Materials](#)

[About the Panel](#)

[Working Groups](#)

[Milestones](#)



BLUE RIBBON PANEL 2016

CANCER MOONSHOT



The Blue Ribbon Panel presented its report to the National Cancer Advisory Board on September 7, 2016. The report describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.

Blue Ribbon Panel Recommendations

- **Network for Direct Patient Engagement**
- Cancer Immunotherapy Translational Science Network
- Therapeutic Target Identification to Overcome Drug Resistance
- **A National Cancer Data Ecosystem for Sharing and Analysis**
- Fusion Oncoproteins in Childhood Cancers
- Symptom Management Research
- Prevention and Early Detection – Implementation of Evidence-based Approaches
- Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care
- Generation of 4D Human Tumor Atlas
- Development of New Enabling Cancer Technologies

Establishing Data Linkages

Cancer Data Ecosystem Implementation Team

Presentation to NAACR Registry of the Future Meeting

June 19, 2017

Cancer Research Data Ecosystem – Cancer Moonshot – NCI Blue Ribbon Panel

Discovery

Proteogenomics
Imaging data
Clinical trials

Patient engaged
Research

Clinical Research
Observational studies

Surveillance
Big Data
Implementation research

EHR, Lab Data, Imaging,
PROs, Smart Devices,
Decision Support

Well characterized
research data sets



**Genomic Data
Commons**

Research information
donor

Cancer cohorts



Active research
participation

Patient data



Real World Data to support
Learning from every
cancer patient

National Cancer Data Ecosystem Recommendation

- Overall goal: Create a data science infrastructure necessary to connect repositories, analytical tools, and knowledge bases.
- Envisioned to consist of multiple components
 - **Fundamental infrastructure** to connect the components and ensure interoperability
 - Common APIs
 - Data schemas
 - Common data dictionaries
 - **Components** such as repositories, analytics services, and interactive portals
- The ability to link diverse data types and data sources is fundamental to interoperability of the Cancer Data Ecosystem

Recommendation 1:

Encrypted unique patient identifier

- Pressing need to connect patient-level data across multiple data generators, data sources, data types
- Need to update information over time
- Challenges:
 - Protecting patient confidentiality
 - Consistency of identifying data (PII) available across resources
 - Accuracy of linkage with varying PII
 - Scalability

Proposed solution: Using secure encryption to develop “tokens” to match on PII

- Using a common software application to generate encrypted hashed tokens
 - Tokens represent various combinations of patient identifiers
 - Provide a secure, encrypted format for data linkages
 - Low probability of re-identification
 - Ability to generate the **same** hashed encrypted identifier from different data sources when using the same software and set of PII
- Benefits of using hashed/encrypted tokens
 - Allows linkage of diverse data sets WITHOUT release of patient identifying information (PII)
 - PII and crosswalk maintained by the parties (data set owners) who are permitted to have PII to enable subsequent linkages

Proposed Process for Encrypted Unique Identifier

Software to generate
encrypted Hashed Token
downloaded and run within Each
Data source (Holder of PII)
**Hashed Token maintained within
each original data source**

Data
Source 1

Cancer
Registry
Data

Genomic
Data

PROs (Pt.
generated
Hash)

Data with
encrypted
unique patient
identifier
Downloaded to
central location
for linkage

Update on
Data
Source 1

**Data linked
via the
encrypted ID**

Combined
dataset created
and available to
the research
community

New data
sources
Added or
existing
information
updated via
same process
as original
linkage


**Newly updated
and combined
dataset created
and available to
the research
community**

PII
maintained
only in
original
permitted
data sources

Potential Role of Cancer Registries

- Common source of PII
 - Required to maintain PII longitudinally over time (name, address, SSN, DOB, gender) on every cancer patient in the US
 - Could serve as the Honest Broker for permitting linkage of datasets where there is a mismatch of PII in two or more datasets wanting to link
 - As an Honest Broker, serve as an arbitrator of any potential mismatches or perceived inconsistencies.
- Opportunity to:
 - provide cancer registry adjudicated structured clinical information about the cancer and its outcomes
 - highlight the value of cancer surveillance and demonstrate new and enhanced utility of our registries

Encrypted Linkage Process Based on Mismatched PII



Potential benefits to cancer research

- Development of well annotated research data sets
 - Clinical data linked to genomic information
- The ability to routinely update existing data
 - Addition of clinical follow-up information on a TCGA patient to genomic information in GDC
- Patients could generate their own encrypted identifier
 - Enables patients to contribute data in a secure manner
 - Essential component of BRP recommendation for Patient Engagement
- Clinical trial eligibility assessment
 - Identification of patient duplication across multiple platforms and data sources without risking patient confidentiality